We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Kodiak Sciences Inc. (KOD - Free Report) . Shares have added about 62.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Kodiak Sciences Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Kodiak’s Q1 Earnings Miss, Pipeline in Focus, Stock Up
Kodiak Sciences reported first-quarter 2023 loss per share of $1.35, wider than the Zacks Consensus Estimate of a loss of $1.28. The company reported a loss of $1.83 per share in the year-ago quarter.
The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues.
Kodiak expects to file a single BLA for tarcocimab in the four major retinal vascular disease indications.
Quarter in Detail
Research and development expenses were approximately $56.5 million in the reported quarter, down about 26% year over year. The decrease was due to the maturation of the company’s tarcocimab clinical program and the timing of manufacturing activities.
General and administrative expenses were $18.1 million, down about 8% on a year-over-year basis, primarily due to lower non-cash stock-based compensation expenses.
As of Mar 31, 2023, Kodiak Sciences had cash, cash equivalents and marketable securities worth $421.2 million compared with $478.9 million as of Dec 31, 2023.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -12.78% due to these changes.
VGM Scores
Currently, Kodiak Sciences Inc. has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Kodiak Sciences Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Kodiak Sciences Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Bluebird Bio (BLUE - Free Report) , has gained 0.8% over the past month. More than a month has passed since the company reported results for the quarter ended March 2023.
Bluebird reported revenues of $2.38 million in the last reported quarter, representing a year-over-year change of +22.1%. EPS of $0.21 for the same period compares with -$1.66 a year ago.
For the current quarter, Bluebird is expected to post a loss of $0.75 per share, indicating a change of +41.9% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.9% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Bluebird. Also, the stock has a VGM Score of F.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?
A month has gone by since the last earnings report for Kodiak Sciences Inc. (KOD - Free Report) . Shares have added about 62.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Kodiak Sciences Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Kodiak’s Q1 Earnings Miss, Pipeline in Focus, Stock Up
Kodiak Sciences reported first-quarter 2023 loss per share of $1.35, wider than the Zacks Consensus Estimate of a loss of $1.28. The company reported a loss of $1.83 per share in the year-ago quarter.
The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues.
Kodiak expects to file a single BLA for tarcocimab in the four major retinal vascular disease indications.
Quarter in Detail
Research and development expenses were approximately $56.5 million in the reported quarter, down about 26% year over year. The decrease was due to the maturation of the company’s tarcocimab clinical program and the timing of manufacturing activities.
General and administrative expenses were $18.1 million, down about 8% on a year-over-year basis, primarily due to lower non-cash stock-based compensation expenses.
As of Mar 31, 2023, Kodiak Sciences had cash, cash equivalents and marketable securities worth $421.2 million compared with $478.9 million as of Dec 31, 2023.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -12.78% due to these changes.
VGM Scores
Currently, Kodiak Sciences Inc. has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Kodiak Sciences Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Kodiak Sciences Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Bluebird Bio (BLUE - Free Report) , has gained 0.8% over the past month. More than a month has passed since the company reported results for the quarter ended March 2023.
Bluebird reported revenues of $2.38 million in the last reported quarter, representing a year-over-year change of +22.1%. EPS of $0.21 for the same period compares with -$1.66 a year ago.
For the current quarter, Bluebird is expected to post a loss of $0.75 per share, indicating a change of +41.9% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.9% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Bluebird. Also, the stock has a VGM Score of F.